Surgical approach to ulcerative colitis: When is the best timing after medical treatment?

Antonino Spinelli, Gianluca M. Sampietro, Piero Bazzi, Matteo Sacchi, Marco Montorsi

Research output: Contribution to journalArticle

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition of the mucosa affecting the rectum and extending up the colon in a continuous manner. Its etiology is unknown, but is most probably the result of the interaction of genetic and environmental factors. Approximately 30% of UC patients will need to undergo surgery at some point during their lifetime, despite progresses made in medical therapies. Indications for surgery include acute severe colitis with its complications, steroid-or antiTNF-refractory colitis (or growth impairment in children), and the onset of colorectal dysplasia/cancer. Recently, the introduction of biologic agents has provided a rationale for prolonging medical therapy before considering surgery in the treatment of active, moderate to severe colitis. When surgery becomes indicated, especially in the urgent setting, it usually involves dealing with immunosuppressive medications, possibly impacting the onset of post-operative septic complications. In both acute and chronic settings, patients should be informed about the medical and surgical options and their respective prognoses; the crucial decision regarding the timing for surgery should be shared by both gastroenterologists and colorectal surgeons. The aim of the present review is to highlight surgical indications and options for UC patients as well as the evidence about surgical complications following medical therapies, in order to aid clinicians in determining the best timing for surgery.

Original languageEnglish
Pages (from-to)1462-1466
Number of pages5
JournalCurrent Drug Targets
Volume12
Issue number10
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Ulcerative Colitis
Surgery
Colitis
Therapeutics
Biological Factors
Immunosuppressive Agents
Rectum
Refractory materials
Colorectal Neoplasms
Colon
Mucous Membrane
Steroids
Growth

Keywords

  • Medications
  • Surgery
  • Therapy
  • Timing
  • Ulcerative colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Surgical approach to ulcerative colitis : When is the best timing after medical treatment? / Spinelli, Antonino; Sampietro, Gianluca M.; Bazzi, Piero; Sacchi, Matteo; Montorsi, Marco.

In: Current Drug Targets, Vol. 12, No. 10, 09.2011, p. 1462-1466.

Research output: Contribution to journalArticle

@article{c1ad306d203e4afe8bf1f676abbeb32b,
title = "Surgical approach to ulcerative colitis: When is the best timing after medical treatment?",
abstract = "Ulcerative colitis (UC) is a chronic inflammatory condition of the mucosa affecting the rectum and extending up the colon in a continuous manner. Its etiology is unknown, but is most probably the result of the interaction of genetic and environmental factors. Approximately 30{\%} of UC patients will need to undergo surgery at some point during their lifetime, despite progresses made in medical therapies. Indications for surgery include acute severe colitis with its complications, steroid-or antiTNF-refractory colitis (or growth impairment in children), and the onset of colorectal dysplasia/cancer. Recently, the introduction of biologic agents has provided a rationale for prolonging medical therapy before considering surgery in the treatment of active, moderate to severe colitis. When surgery becomes indicated, especially in the urgent setting, it usually involves dealing with immunosuppressive medications, possibly impacting the onset of post-operative septic complications. In both acute and chronic settings, patients should be informed about the medical and surgical options and their respective prognoses; the crucial decision regarding the timing for surgery should be shared by both gastroenterologists and colorectal surgeons. The aim of the present review is to highlight surgical indications and options for UC patients as well as the evidence about surgical complications following medical therapies, in order to aid clinicians in determining the best timing for surgery.",
keywords = "Medications, Surgery, Therapy, Timing, Ulcerative colitis",
author = "Antonino Spinelli and Sampietro, {Gianluca M.} and Piero Bazzi and Matteo Sacchi and Marco Montorsi",
year = "2011",
month = "9",
doi = "10.2174/138945011796818199",
language = "English",
volume = "12",
pages = "1462--1466",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Surgical approach to ulcerative colitis

T2 - When is the best timing after medical treatment?

AU - Spinelli, Antonino

AU - Sampietro, Gianluca M.

AU - Bazzi, Piero

AU - Sacchi, Matteo

AU - Montorsi, Marco

PY - 2011/9

Y1 - 2011/9

N2 - Ulcerative colitis (UC) is a chronic inflammatory condition of the mucosa affecting the rectum and extending up the colon in a continuous manner. Its etiology is unknown, but is most probably the result of the interaction of genetic and environmental factors. Approximately 30% of UC patients will need to undergo surgery at some point during their lifetime, despite progresses made in medical therapies. Indications for surgery include acute severe colitis with its complications, steroid-or antiTNF-refractory colitis (or growth impairment in children), and the onset of colorectal dysplasia/cancer. Recently, the introduction of biologic agents has provided a rationale for prolonging medical therapy before considering surgery in the treatment of active, moderate to severe colitis. When surgery becomes indicated, especially in the urgent setting, it usually involves dealing with immunosuppressive medications, possibly impacting the onset of post-operative septic complications. In both acute and chronic settings, patients should be informed about the medical and surgical options and their respective prognoses; the crucial decision regarding the timing for surgery should be shared by both gastroenterologists and colorectal surgeons. The aim of the present review is to highlight surgical indications and options for UC patients as well as the evidence about surgical complications following medical therapies, in order to aid clinicians in determining the best timing for surgery.

AB - Ulcerative colitis (UC) is a chronic inflammatory condition of the mucosa affecting the rectum and extending up the colon in a continuous manner. Its etiology is unknown, but is most probably the result of the interaction of genetic and environmental factors. Approximately 30% of UC patients will need to undergo surgery at some point during their lifetime, despite progresses made in medical therapies. Indications for surgery include acute severe colitis with its complications, steroid-or antiTNF-refractory colitis (or growth impairment in children), and the onset of colorectal dysplasia/cancer. Recently, the introduction of biologic agents has provided a rationale for prolonging medical therapy before considering surgery in the treatment of active, moderate to severe colitis. When surgery becomes indicated, especially in the urgent setting, it usually involves dealing with immunosuppressive medications, possibly impacting the onset of post-operative septic complications. In both acute and chronic settings, patients should be informed about the medical and surgical options and their respective prognoses; the crucial decision regarding the timing for surgery should be shared by both gastroenterologists and colorectal surgeons. The aim of the present review is to highlight surgical indications and options for UC patients as well as the evidence about surgical complications following medical therapies, in order to aid clinicians in determining the best timing for surgery.

KW - Medications

KW - Surgery

KW - Therapy

KW - Timing

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=80051695549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051695549&partnerID=8YFLogxK

U2 - 10.2174/138945011796818199

DO - 10.2174/138945011796818199

M3 - Article

C2 - 21466484

AN - SCOPUS:80051695549

VL - 12

SP - 1462

EP - 1466

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -